Duvyzat®▼ (givinostat): interim advice on risk mitigation measures following reports of deaths in patients while taking givinostat
Authored by Medicines and Healthcare products Regulatory Agency (MHRA)Originally published 5 Nov 2026
Meets Patient’s editorial guidelines
- DownloadDownload
- Share
- Language
- Discussion
- Ask Patient
- Audio Version
- Add to preferred sources on Google
Medical Professionals
Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find one of our health articles more useful.
There have been several reports internationally of deaths in patients with Duchenne muscular dystrophy (DMD) while being treated with Duvyzat® (givinostat). Following a review of these cases and associated evidence, the MHRA…
Read the full update from MHRA
About MHRA alerts and recalls
The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for medicines, vaccines and medical devices. One of its key responsibilities is to monitor the safety and effectiveness of products in use across the NHS and wider healthcare system. When new safety concerns are identified, or when issues arise with the manufacture or distribution of a medicine or device, the MHRA issues alerts and recalls to protect patients and support healthcare professionals.
These alerts can take several forms. Some provide updated guidance on prescribing or monitoring requirements for medicines and vaccines. Others may highlight newly recognised side effects, or remind clinicians of important risk-mitigation steps. In the case of medical devices, alerts may cover field safety notices, product recalls, or urgent device modifications. All of these communications are designed to ensure that products are used safely and that any risks are managed appropriately.
Patient.info republishes MHRA alerts and recalls so that this information is available quickly and accessibly to both healthcare professionals and the public. The summary above is taken directly from the MHRA’s official publication. To read the full advice, including detailed recommendations for prescribers, manufacturers and patients, please follow the “Read more” link to the MHRA website.
If you are a healthcare professional, you should consult the full notice to confirm the latest prescribing information, monitoring requirements and any actions you need to take in your practice. If you are a patient or carer, do not stop treatment or make changes to your medication or device without first seeking professional advice. If you have any concerns about your medicine or device, speak to your GP, pharmacist or specialist nurse.
Contains public sector information licensed under the Open Government Licence v3.0.
Patient picks for Alerts, recalls and safety information

Professional
Antidepressants: new safety measures for all patients to improve communication of the risk of suicidal thoughts and behaviours and persistent sexual dysfunction
New safety measures are now being implemented to improve how the risks of suicidal thoughts and behaviours and persistent sexual dysfunction are communicated to patients taking antidepressant medications. Read the full update from MHRA About MHRA alerts and recalls The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s.
by Medicines and Healthcare products Regulatory Agency (MHRA)
%3A%20Consider%20delayed%20administration%20of%20concurrent%20echinocandins%2C%20such%20as%20caspofungin%2C%20to%20reduce%20the%20risk%20of%20adsorption%20onto%20new%20polyacrylonitrile%20(PAN)-based%20filter%20membranes%20DSI%2F2026%2F014/og.png)
Professional
Continuous renal replacement therapy (CRRT): Consider delayed administration of concurrent echinocandins, such as caspofungin, to reduce the risk of adsorption onto new polyacrylonitrile (PAN)-based filter membranes DSI/2026/014
Continuous renal replacement therapy (CRRT) is used for managing severe acute kidney injury and fluid overload. Read the full update from MHRA About MHRA alerts and recalls The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for medicines, vaccines and medical devices. ...across the NHS and wider healthcare.
by Medicines and Healthcare products Regulatory Agency (MHRA)

Professional
Nova Biomedical StatStrip ketone test strips: risk of disruption to blood ketone testing due to quality-control failures and supply interruption DSI/2026/013
Nova Biomedical has identified quality issues affecting specified lots of StatStrip ketone test strips. Read the full update from MHRA About MHRA alerts and recalls The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for medicines, vaccines and medical devices. One of its key responsibilities is to monitor the s....
by Medicines and Healthcare products Regulatory Agency (MHRA)

Professional
IXCHIQ Chikungunya vaccine: UK marketing authorisation withdrawn following safety review
Following advice from the Commission on Human Medicines (CHM), the MHRA has concluded that the benefit-risk balance for the IXCHIQ chikungunya vaccine is no longer considered favourable and the UK marketing authorisation has. Read the full update from MHRA About MHRA alerts and recalls The Medicines and Healthcare products Regulatory Agency (MHRA).
by Medicines and Healthcare products Regulatory Agency (MHRA)

Professional
Filters should be used during the administration of Parenteral Nutrition for patients in all care settings
...tion of parenteral nutrition without a filter has been associated with a number of adverse incidents including an embolism which resulted in a fatal outcomeRead the full update from MHRA About MHRA alerts and recalls The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for medicines, vaccines and medical devices..
by Medicines and Healthcare products Regulatory Agency (MHRA)

Professional
Filters should be used during the administration of Parenteral Nutrition for patients in all care settings DSI/2026/011
Administration of parenteral nutrition without a filter has been associated with a number of adverse incidents including an embolism which resulted in a fatal... Read the full update from MHRA About MHRA alerts and recalls The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for medicines, vaccines and medical.
by Medicines and Healthcare products Regulatory Agency (MHRA)
Exclusive updates for healthcare professionals
Stay informed with the latest clinical updates, professional insights, and evidence-based guidance. The Patient Pro newsletter curates essential content for healthcare professionals—delivered straight to your inbox.
By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.
Article history
Article also available in English, German, Spanish, French, Italian, Portuguese, Hindi, Hebrew, Arabic, and Swedish.
5 Nov 2026 | Originally published
Authored by:
Medicines and Healthcare products Regulatory Agency (MHRA)
More in alerts, recalls and safety information
- Belzer UW® Cold Storage Solution and Belzer MPS® (UW Machine Perfusion Solution): manufactured by Carnamedica (UKRP: Bridge to Life): Updated advice on the contamination of fluid DSI/2026/006 (update to DSI/2023/005)
- Class 2 Medicines Recall: Baxter Healthcare Limited, Compound Sodium Lactate Solution for Infusion BP (Hartmann's Solution for infusion) in Viaflo 1000ml, EL(25)A/46
- Class 2 Medicines Recall: Bio Products Laboratory Limited, Rabies, Human normal Immunoglobulin 500IU solution for Injection, EL(26)A/18
- Class 3 Medicines Recall: Aspar Pharmaceuticals Ltd, Ibuprofen 200mg Tablets, Ibucalm 200mg tablets, EL(26)A/07
- Class 3 Medicines Recall: Bayer Plc, Various Products, EL(26)A/12
- Class 3 Medicines Recall: Norgine Limited, MOVICOL Ease Citrus Powder for oral solution 13.7 g, EL(26)A/08
- Class 4 Medicines Defect Notification: Relonchem Ltd, Various Products, EL(25)A/44
- NewClass 4 Medicines Defect Notification: Star Pharmaceuticals Ltd, Enalapril maleate/ Hydrochlorothiazide 20 mg/12.5 mg Tablets, EL(26)A/48
- Field Safety Notices: 5 to 9 October 2026
- Field Safety Notices: 6 October to 10 October 2025
- Field Safety Notices: 8 -12 June 2026
- Field Safety Notices: 9 - 13 March 2026
- Field Safety Notices: 09-13 February 2026
- Field Safety Notices: 10 to 14 November 2025
- Field Safety Notices: 12 October 2026 to 16 October 2026
- Field Safety Notices: 13 to 17 April 2026
- Field Safety Notices: 15 - 19 December 2025
- Field Safety Notices: 16-20 February 2026
- Field Safety Notices: 20 to 24 October 2025
- Field Safety Notices: 29 December 2025 to 2 January 2026


